-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, global biomedicine is setting off a financing wave
.
According to incomplete statistics, in China, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year alone has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
This financing wave is still going on.
In the recent past, many innovative pharmaceutical companies have announced the completion of financing, mostly in the hundreds of millions of dollars
.
On December 27, Zezheng Pharmaceutical announced that it has officially completed the B round of financing of more than 100 million yuan, and the new round of financing will be exclusively invested by Renhe Capital
.
So far, Zezheng Pharmaceutical has completed two rounds of financing in 2021, with a total amount of nearly RMB 300 million
.
Public information shows that Zezheng Medicine was established in 2016 and is a pharmaceutical research and development enterprise focusing on high-end modified preparations
.
In February of this year, Zezheng Pharmaceuticals received more than 100 million yuan of financing from Morningside Ventures, and it has in-depth layout of small nucleic acid and peptide drug delivery systems, small molecule nano preparations and children's preparations, and has built a pilot plant that meets GMP standards.
.
After the completion of this round of financing, Zezheng Medicine will advance the construction of its six major technology platforms at a faster speed, recruit talents, and work with strategic partners to advance the products in the pipeline into the clinical stage
.
On the same day, Suzhou Omini Pharmaceutical Co.
, Ltd.
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, also announced that it has completed the D round of financing of hundreds of millions of yuan.
This round of financing is led by the Shanghai Biomedical Fund.
Investment, Bank of China Investment (BOCGI), Taikun Capital, Yuanlai Capital, Zhongxin Capital, Zhang Keherun followed the investment
.
It is understood that Omini Pharmaceuticals was established in 2011.
Its R&D center is located in Shanghai Zhangjiang Medicine Valley, and its two production bases are located in Suzhou and Haimen, Jiangsu
.
As one of the few domestic pharmaceutical companies that have entered the field of respiratory inhalation preparations, Omini has many advantages in preparation development and device design
.
Regarding the fundraising, it stated that the funds raised in the financing will be used for the advancement of clinical research and R&D pipelines of multiple projects, as well as commercial operations
.
In addition, not long ago, Shanghai Yinnuo Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as “Yinnuo Pharmaceutical”) also announced that it has completed a US$120 million Series A financing, led by Youshan Capital and jointly led by Huachuang Capital.
CICC The capital's CICC Kai Tak Fund, V Star Capital (V Star Capital), Langmafeng Venture Capital, Deyi Capital, Everbright Holdings, Xiaochi Capital, Guoke Jiahe, and Pudong Investment Control followed in the investment
.
It is reported that this round of financing will be used for the global phase 3 clinical trials of suparutide, the promotion of multiple potential "first-in-class" pipeline products, and the construction of cGMP production bases
.
From the perspective of the industry, behind the continuous financing of pharmaceutical companies is actually a manifestation of the continuous rise of China's biomedical industry
.
In recent years, with the support of favorable policies, in the context of the continuous growth of the domestic pharmaceutical market and the increasing acceptance of innovative therapies in the country, local innovative companies are continuously developing innovative drugs and expanding internationally through financing.
Market
.
According to the current industry development status, it is expected that more and more innovative companies will attract the attention of strategic investors in the future
.
And this will also inject more momentum into the pharmaceutical and biological market, thereby better promoting the innovation and high-quality development of the pharmaceutical and biological industry
.
.
According to incomplete statistics, in China, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year alone has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
This financing wave is still going on.
In the recent past, many innovative pharmaceutical companies have announced the completion of financing, mostly in the hundreds of millions of dollars
.
On December 27, Zezheng Pharmaceutical announced that it has officially completed the B round of financing of more than 100 million yuan, and the new round of financing will be exclusively invested by Renhe Capital
.
So far, Zezheng Pharmaceutical has completed two rounds of financing in 2021, with a total amount of nearly RMB 300 million
.
Public information shows that Zezheng Medicine was established in 2016 and is a pharmaceutical research and development enterprise focusing on high-end modified preparations
.
In February of this year, Zezheng Pharmaceuticals received more than 100 million yuan of financing from Morningside Ventures, and it has in-depth layout of small nucleic acid and peptide drug delivery systems, small molecule nano preparations and children's preparations, and has built a pilot plant that meets GMP standards.
.
After the completion of this round of financing, Zezheng Medicine will advance the construction of its six major technology platforms at a faster speed, recruit talents, and work with strategic partners to advance the products in the pipeline into the clinical stage
.
On the same day, Suzhou Omini Pharmaceutical Co.
, Ltd.
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, also announced that it has completed the D round of financing of hundreds of millions of yuan.
This round of financing is led by the Shanghai Biomedical Fund.
Investment, Bank of China Investment (BOCGI), Taikun Capital, Yuanlai Capital, Zhongxin Capital, Zhang Keherun followed the investment
.
It is understood that Omini Pharmaceuticals was established in 2011.
Its R&D center is located in Shanghai Zhangjiang Medicine Valley, and its two production bases are located in Suzhou and Haimen, Jiangsu
.
As one of the few domestic pharmaceutical companies that have entered the field of respiratory inhalation preparations, Omini has many advantages in preparation development and device design
.
Regarding the fundraising, it stated that the funds raised in the financing will be used for the advancement of clinical research and R&D pipelines of multiple projects, as well as commercial operations
.
In addition, not long ago, Shanghai Yinnuo Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as “Yinnuo Pharmaceutical”) also announced that it has completed a US$120 million Series A financing, led by Youshan Capital and jointly led by Huachuang Capital.
CICC The capital's CICC Kai Tak Fund, V Star Capital (V Star Capital), Langmafeng Venture Capital, Deyi Capital, Everbright Holdings, Xiaochi Capital, Guoke Jiahe, and Pudong Investment Control followed in the investment
.
It is reported that this round of financing will be used for the global phase 3 clinical trials of suparutide, the promotion of multiple potential "first-in-class" pipeline products, and the construction of cGMP production bases
.
From the perspective of the industry, behind the continuous financing of pharmaceutical companies is actually a manifestation of the continuous rise of China's biomedical industry
.
In recent years, with the support of favorable policies, in the context of the continuous growth of the domestic pharmaceutical market and the increasing acceptance of innovative therapies in the country, local innovative companies are continuously developing innovative drugs and expanding internationally through financing.
Market
.
According to the current industry development status, it is expected that more and more innovative companies will attract the attention of strategic investors in the future
.
And this will also inject more momentum into the pharmaceutical and biological market, thereby better promoting the innovation and high-quality development of the pharmaceutical and biological industry
.
